Xpovio is a first-in-class oral selective inhibitor of the nuclear export protein exportin-1 (XPO1). Xpovio is believed to bind with and inhibit XPO1, causing tumor suppressor proteins to accumulate in the cell nucleus and inducing apoptosis in cancer cells while preserving normal cells. It is indicated to treat patients with heavily pretreated relapsed/refractory multiple myeloma.

If you have a Hayes login, click here to view the full report on the Knowledge Center.